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ABSTRACT 25 
RFLP and DNA sequencing of PCR products showed that a Lactobacillus rhamnosus 26 
strain of human origin resistant to macrolides, from which no resistance determinants 27 
have been detected by specific PCR and microarray screening, contained a 28 
heterozygous A-to-G transition mutation at position 2058 (Escherichia coli numbering) 29 
of its 23S rRNA gene. 30 
 31 
The resistance gene reservoir hypothesis suggests that beneficial and commensal 32 
bacterial populations in food and the gastrointestinal tract (GIT) of animals and humans 33 
may play a role in the transfer of antibiotic resistance (Teuber et al., 1999; Salyers et 34 
al., 2004). To reduce the spread of such resistance, the appropriate use of antibiotics is 35 
important (MARAN, 2002; DANMAP, 2003), as is the screening for antibiotic 36 
resistance in bacteria intended to be used in food systems (Teuber et al., 1999; 37 
European Commission, 2005). Distinguishing between intrinsic and acquired resistance 38 
is essential, and with respect to the latter it is important to determine whether it is 39 
caused by genomic mutation or added genes; the last of these poses the greatest risk of 40 
horizontal transmission (Maiden, 1998; Normak and Normak, 2002). 41 
Lactobacillus species are members of the lactic acid bacteria (LAB) group, and are 42 
capable of colonising habitats as diverse as fresh and fermented plant materials, meat 43 
products, fish, dairy, sourdoughs, fermented beverages, and the human and animal GIT 44 
(Kandler and Weiss, 1986). The use of selected species of lactobacilli as starter 45 
organisms in industrial food and feed fermentations has a long tradition (Cogan, 1996; 46 
Bernardau et al., 2006). Moreover, the lactobacilli form one of the subdominant 47 
bacterial populations of the human and animal GIT (Vaughan et al., 2002), where they 48 
are thought to exert an array of beneficial effects, including the inhibition of pathogens, 49 
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the alleviation of lactose intolerance, the boosting of the immune response, and the 50 
lowering of cholesterol levels. Benefit is also derived from their possible anti-51 
carcinogenic and anti-mutagenic activities, etc. (Ouwehand et al., 2002; Sanders, 2003). 52 
Erythromycin and other macrolides are the best alternatives for the treatment of 53 
penicillin-allergic patients. Bacterial resistance to macrolides, lincosamides and 54 
streptogramins (MLS phenotype) is often due to efflux systems, methylases, and 55 
inactivating enzymes, for which more than 40 genes have been reported (Roberts et al., 56 
1999a). However, it can also be due to mutations in ribosomal proteins L4 and L22 or in 57 
the 23S rRNA molecule (Leclercq, 2002). In fact, chromosomal mutations altering the 58 
erythromycin binding site in the V domain of the 23S rRNA gene (at cognate position 59 
A2058 [Escherichia coli numbering]) has been shown in a number of clinical isolates, 60 
including Mycoplasma spp. (Meier et al., 1994; Lucier et al., 1995), Helicobacter pylori 61 
(Versalovic et al., 1996), Propionibacterium spp. (Ross et al., 1997), and Bordetella 62 
pertussis (Bartkus et al., 2003). Here we report on the identification of a 23S rRNA 63 
mutation in a Lactobacillus rhamnosus strain conferring resistance to erythromycin, 64 
clindamycin and some other macrolides, in which PCR and microarray screening 65 
techniques have failed to identify any macrolide resistance genes. To our knowledge, 66 
this is the first report of such a mutation in an LAB species. 67 
 68 
Minimum inhibitory concentration (MIC) of macrolides for L. rhamnosus E41. 69 
During a recent survey, two L. rhamnosus isolates were identified as resistant to both 70 
erythromycin (MIC 1024 µg ml-1) and clindamycin (MIC 256 µg ml-1) in a microbroth 71 
assay (Delgado et al., 2005). Resistance to these antibiotics is confirmed in the present 72 
work by the Etest method (AB Biodisk, Solna, Sweden). In contrast, the MICs of 73 
erythromycin and clindamycin in susceptible L. rhamnosus isolates (E51, G92, G94, 74 
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E52, E57, F46) and the industrial probiotic strain L. rhamnosus LMG 18243 (strain 75 
GG) were 1 and 0.5 µg ml-1 respectively. Typing of the isolates by phenotypic (API50 76 
CHL, bioMérieux, Montalieu-Vercieu, France) and genetic (random amplification of 77 
polymorphic DNA) methods identified them as the same strain.  78 
 79 
Identification of erythromycin resistance determinants in L. rhamnosus E41. 80 
Genes ermA, erm(B), erm(C), erm(F) and mef(A), which confer macrolide resistance, 81 
are widely distributed among Gram positive and Gram negative organisms (Jensen et 82 
al., 1999). Some have already been characterized in plasmids (Tannock et al., 1994; 83 
Fons et al., 1997; Gfeller et al., 2003) and on the chromosome (Flórez et al., 2006) of 84 
lactobacillus species. In the present study, the presence of these five genes was 85 
therefore analysed by specific PCR using purified total DNA from E41 as a template. 86 
The primers and PCR conditions used were those reported by Roberts et al. (1999b). 87 
No amplification was obtained with any of the specific primer couples. Analysis of two 88 
original L. rhamnosus isolates for resistance genes using DNA microarrays with more 89 
than 300 oligonucleotide probes, of which 42 corresponded to genes involved in MLS 90 
phenotype, also returned negative results (Ammor et al., 2006). 91 
 92 
PCR amplification and analysis of 23S rRNA gene sequences. After ruling out the 93 
presence of added genes as responsible for the MLS phenotype in strain E41, a search 94 
for mutations in its ribosomal components was performed. The L. rhamnosus sequences 95 
for the genes encoding the L4 and L22 proteins, and that of 23S RNA, are not available 96 
in public databases. Therefore to amplify a segment of the 23S RNA gene, including 97 
the critical 2048 residue (E. coli 23S rRNA numbering) involved in macrolide 98 
resistance, we made use of the recently described universal primers 1104f and 2241r 99 
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(Hunt et al., 2006). For comparison, the same segment of the 23S rRNA from seven 100 
erythromycin- and clindamycin-susceptible strains, including L. rhamnosus GG, was 101 
amplified under identical conditions. An amplicon of around 1200 bp was obtained 102 
from all strains. This was purified using the Gen Elute PCR Clean Up kit (Sigma 103 
Chemical Co., St. Louis, Mo., USA) and subjected to restriction fragment length 104 
polymorphism (RFLP) analysis and sequencing. 105 
The transition mutation from A to G at position 2058 in the erythromycin-resistant 106 
23S rRNA sequence introduces a recognition site for the restriction enzyme BbsI. Thus, 107 
amplicons were all digested with this enzyme - which anticipates the mutation - before 108 
analysis of the sequences. Fragments of the expected size were only observed in the 109 
amplicon obtained from the erythromycin-resistant strain (Fig. 1, line 1). However, part 110 
of the amplicon appeared to be undigested, suggesting either partial digestion with BbsI 111 
had occurred, or the simultaneous presence of wild-type and mutant copies of the 23S 112 
rRNA gene. As a control, amplicons were also digested with HindIII, the cleavage site 113 
of which is in the middle of the amplified region in the 23S rRNA sequences of many 114 
lactobacillus species. With this enzyme, all the amplicons were digested, giving rise to 115 
identical fragments. This supports the idea of heterozygosity for the 23S rRNA genes in 116 
the L. rhamnosus E41 studied.  117 
To support these results, all amplicons were sequenced in an ABI PRISM 370 118 
sequencer (Applied Biosystems, Foster City, Ca., USA), and the sequences obtained 119 
were compared to one another and to those in databases. In the sequence corresponding 120 
to the resistant strain, a transition mutation (A to G) was observed at the corresponding 121 
position of 2058; this was not seen in the susceptible strains (Fig. 2). The 122 
chromatograms showed a fluorescence signal for an adenine residue in E41 as well as 123 
in the wild-type susceptible strains, indicating its heterozygous status. Although no 124 
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information is available on the number of rRNA operons in L. rhamnosus, it is expected 125 
to range from four to seven, as in other Lactobacillus species (Klaenhammer et al., 126 
2002). The sequences obtained in this work showed the highest homology (97%) to a 127 
partial sequence of the L. casei 23S rRNA gene (accession no. AF098107), and 128 
significant homology (93%) to the 23S rRNA sequences from other lactobacilli and 129 
enterococci. Comparing the wild-type and mutant sequencing signals in the resistant 130 
strain with the signal of the restriction fragments digested with BbsI, it is tempting to 131 
speculate that more than one copy of the mutated sequence is present in the L. 132 
rhamnosus L42 23S gene.  133 
 134 
In conclusion, this paper reports a chromosomal mutation of the 23S rRNA gene as the 135 
most plausible cause of macrolide resistance in L. rhamnosus E41. Analysis of other 136 
ribosomal components thought to be involved in macrolide resistance should exclude 137 
other possibilities. Lactobacillus rhamnosus E41 shows promising probiotic properties 138 
(Delgado and Mayo, unpublished); it would be especially useful to people undergoing 139 
long-term macrolide treatment. 140 
 141 
Nucleotide sequence accession numbers. The wild-type and mutant 23S rRNA gene 142 
sequences of L. rhamnosus were assigned GenBank accession nos. EF030190 and 143 
EF030191, respectively. 144 
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Figure Legends 
 
 
Figure 1. PCR restriction fragment length polymorphism (RFLP) analysis of 23S gene 
amplicons from the macrolide resistant strain Lactobacillus rhamnosus E41 (line 1) and a 
series of L. rhamnosus susceptible strains [E51, G92, G94, E52, E57, F46 and LMG 18243 
(strain GG); lines 2 through 8, respectively] digested with the restriction enzymes BbsI 
(left) and HindIII (right). M, molecular weight marker. 
 
Figure 2. Representative sequence chromatograms of 23S rRNA genes for the wild type 
macrolide-susceptible Lactobacillus rhamnosus LMG 18243 (strain GG) (left) and that of 
the macrolide-resistance L. rhamnosus E41 (right). Arrows indicate the nucleotide at 
position 2058 (of the Escherichia coli numbering). Note the heterozygous nature (G/A) of 
strain E41 at this position. 
 
